Advertisement

Adalimumab

  • Giuseppe TridenteEmail author
Chapter

Abstract

Adalimumab (Humira®, Abbott) is a recombinant fully human IgG1/2 k anti-TNFα monoclonal antibody approved in 2002 by FDA and in 2003 by EMEA (simultaneous submission). During the following years this monoclonal spread over 62 countries to be used in a wide series of immune-mediated inflammatory diseases (IMID). Initially indicated for the treatment of rheumatoid arthritis (RA), between 2005 and 2008 it was progressively extended to psoriasic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), plaque psoriasis (Ps), and juvenile idiopathic arthritis (JIA). During 2012, adalimumab was also approved by EMEA for the treatment of ulcerative colitis (UC) and for moderate forms of CD and other inflammatory bowel diseases (IBD) in adult patients. Other approvals regarding extended applications of previously authorized diseases treatments are pending. Up to 2012, over 70 trials were performed for the six official therapeutic indications, including pivotal trials submitted for drug approvals. Overall, most data come from RA studies (over 14,000 subjects), followed by the more recent ones on CD and Psoriasis (over 3,000 subjects each) stimulated by the possibility of an extension of the treatment to these patients.

Keywords

Ankylose Spondylitis Juvenile Idiopathic Arthritis Juvenile Idiopathic Arthritis Patient Erythema Multiforme Hidradenitis Suppurativa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_6_MOESM1_ESM.xls (74 kb)
Supplementary material 1 (XLS 75 kb)

References

  1. 1.
    Humira (Adalimumab) BLA125057 Clinical Review Part V Dec 2002Google Scholar
  2. 2.
    Humira (Adalimumab) Product Monograph. Abbott Lab, Canada, Apr 2011Google Scholar
  3. 3.
    Humira (Adalimumab) Prescribing Information. Abbott Sep 2012Google Scholar
  4. 4.
    Humira (Adalimumab). EPAR WC500050870, EMEA, July 2012Google Scholar
  5. 5.
    Humira (Adalimumab). EPAR WC500126007, EMEA, Mar 2012Google Scholar
  6. 6.
    Humira (Adalimumab). EPAR WC500138422, EMEA, Oct 2012Google Scholar
  7. 7.
    Humira (Adalimumab). EPAR WC500142038, EMEA, Jan 2013Google Scholar
  8. 8.
    Vena GA, Cassano N (2007) Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics 1:93–103PubMedGoogle Scholar
  9. 9.
    Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117:244–279PubMedCrossRefGoogle Scholar
  10. 10.
    Bissonnette R, Bolduc C, Poulin Y et al (2010) Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 63:229–234Google Scholar
  11. 11.
    Horiuchi T, Mitoma H, Harashima S et al (2010) Transmembrane TNFα: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228PubMedCrossRefGoogle Scholar
  12. 12.
    Wick MC, Ernestam S, Lindblad S et al (2005) Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE Registry at Karolinska University Hospital. Scand J Rheumatol 34:353–358PubMedCrossRefGoogle Scholar
  13. 13.
    Furst DE, Wallis R, Broder M et al (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159–167PubMedCrossRefGoogle Scholar
  14. 14.
    Gordon KB, Bonish BK, Patel T et al (2005) The tumor necrosis factor-α inhibitor adalimumab reverses the decrease in epidermal Langerhans cell density in psoriasis plaques. Br J Dermatol 153:945–953PubMedCrossRefGoogle Scholar
  15. 15.
    Humira (Adalimumab) EPAR WC500050867, EMEA. Mar 2006Google Scholar
  16. 16.
    Burmester GR, Panaccione R, Gordon KB et al (2012) Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, ankylosing spondylitis, psoriasic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-201244 Google Scholar
  17. 17.
    Carmona L, Descalzo MA, Ruiz-Montesinos D et al (2011) Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish Registry BIOBADSER 2.0. Rheumatology 50:65–92CrossRefGoogle Scholar
  18. 18.
    Diaz-Ley B, Guhl G, Fernández-Herrera J (2007) Off-label use of biologic agents in the treatment of dermatosis, Part 1: infliximab and adalimumab. Actas Dermosifiliogr. 2007;98:657-78Google Scholar
  19. 19.
    Carroll MB, Forgione A (2010) Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanism of action. Clin Rheumatol 29:1021–1029PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations